AtriCure, Inc.

NasdaqGM:ATRC Lagerbericht

Marktkapitalisierung: US$1.2b

AtriCure Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

AtriCure wird ein jährliches Gewinn- und Umsatzwachstum von 19.2% bzw. 12.8% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 20.5% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -6.2% betragen.

Wichtige Informationen

22.2%

Wachstumsrate der Gewinne

25.1%

EPS-Wachstumsrate

Medical Equipment Gewinnwachstum17.4%
Wachstumsrate der Einnahmen12.8%
Zukünftige Eigenkapitalrendite-5.4%
Analystenabdeckung

Good

Zuletzt aktualisiert31 Jul 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Analysts Have Been Trimming Their AtriCure, Inc. (NASDAQ:ATRC) Price Target After Its Latest Report

Aug 02
Analysts Have Been Trimming Their AtriCure, Inc. (NASDAQ:ATRC) Price Target After Its Latest Report

Recent updates

Analysts Have Been Trimming Their AtriCure, Inc. (NASDAQ:ATRC) Price Target After Its Latest Report

Aug 02
Analysts Have Been Trimming Their AtriCure, Inc. (NASDAQ:ATRC) Price Target After Its Latest Report

AtriCure's Latest Projects And European Market Entry, Advancing Cardiac Care

Jul 25

AtriCure, Inc. (NASDAQ:ATRC) Soars 26% But It's A Story Of Risk Vs Reward

Jul 18
AtriCure, Inc. (NASDAQ:ATRC) Soars 26% But It's A Story Of Risk Vs Reward

AtriCure, Inc.'s (NASDAQ:ATRC) Intrinsic Value Is Potentially 88% Above Its Share Price

May 30
AtriCure, Inc.'s (NASDAQ:ATRC) Intrinsic Value Is Potentially 88% Above Its Share Price

Positive Sentiment Still Eludes AtriCure, Inc. (NASDAQ:ATRC) Following 29% Share Price Slump

Apr 04
Positive Sentiment Still Eludes AtriCure, Inc. (NASDAQ:ATRC) Following 29% Share Price Slump

Does AtriCure (NASDAQ:ATRC) Have A Healthy Balance Sheet?

Mar 14
Does AtriCure (NASDAQ:ATRC) Have A Healthy Balance Sheet?

Investors Interested In AtriCure, Inc.'s (NASDAQ:ATRC) Revenues

Jan 21
Investors Interested In AtriCure, Inc.'s (NASDAQ:ATRC) Revenues

Is AtriCure (NASDAQ:ATRC) Using Debt In A Risky Way?

Nov 29
Is AtriCure (NASDAQ:ATRC) Using Debt In A Risky Way?

AtriCure, Inc.'s (NASDAQ:ATRC) Intrinsic Value Is Potentially 99% Above Its Share Price

Sep 27
AtriCure, Inc.'s (NASDAQ:ATRC) Intrinsic Value Is Potentially 99% Above Its Share Price

Health Check: How Prudently Does AtriCure (NASDAQ:ATRC) Use Debt?

Aug 02
Health Check: How Prudently Does AtriCure (NASDAQ:ATRC) Use Debt?

AtriCure, Inc.'s (NASDAQ:ATRC) Share Price Matching Investor Opinion

Jun 15
AtriCure, Inc.'s (NASDAQ:ATRC) Share Price Matching Investor Opinion

Is AtriCure (NASDAQ:ATRC) Weighed On By Its Debt Load?

Apr 14
Is AtriCure (NASDAQ:ATRC) Weighed On By Its Debt Load?

Calculating The Intrinsic Value Of AtriCure, Inc. (NASDAQ:ATRC)

Mar 02
Calculating The Intrinsic Value Of AtriCure, Inc. (NASDAQ:ATRC)

What Does AtriCure, Inc.'s (NASDAQ:ATRC) Share Price Indicate?

Feb 09
What Does AtriCure, Inc.'s (NASDAQ:ATRC) Share Price Indicate?

Is AtriCure (NASDAQ:ATRC) Using Debt In A Risky Way?

Dec 28
Is AtriCure (NASDAQ:ATRC) Using Debt In A Risky Way?

Is Now An Opportune Moment To Examine AtriCure, Inc. (NASDAQ:ATRC)?

Sep 06
Is Now An Opportune Moment To Examine AtriCure, Inc. (NASDAQ:ATRC)?

An Intrinsic Calculation For AtriCure, Inc. (NASDAQ:ATRC) Suggests It's 29% Undervalued

Aug 02
An Intrinsic Calculation For AtriCure, Inc. (NASDAQ:ATRC) Suggests It's 29% Undervalued

AtriCure: 5x Sales For A Series Of Impeding Losses? No Thanks

Jun 13

Is AtriCure (NASDAQ:ATRC) Weighed On By Its Debt Load?

Jun 08
Is AtriCure (NASDAQ:ATRC) Weighed On By Its Debt Load?

Is It Time To Consider Buying AtriCure, Inc. (NASDAQ:ATRC)?

May 08
Is It Time To Consider Buying AtriCure, Inc. (NASDAQ:ATRC)?

Gewinn- und Umsatzwachstumsprognosen

NasdaqGM:ATRC - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
DatumUmsatzGewinneFreier CashflowBargeld aus operativen TätigkeitenDurchschn. Anz. Analysten
12/31/2026585-2122417
12/31/2025520-299259
12/31/2024458-38-1129
6/30/2024430-40-20-8N/A
3/31/2024415-37-55-12N/A
12/31/2023399-30-384N/A
9/30/2023381-25-131N/A
6/30/2023366-28-48-3N/A
3/31/2023349-38-18-2N/A
12/31/2022330-46-39-22N/A
9/30/2022316-56-37-22N/A
6/30/202230353-32-20N/A
3/31/202229052-41-29N/A
12/31/202127450-24-14N/A
9/30/202125945-18-10N/A
6/30/2021243-57-14-6N/A
3/31/2021213-49-18-13N/A
12/31/2020207-48-25-20N/A
9/30/2020210-46-36-27N/A
6/30/2020212-50-44-34N/A
3/31/2020230-46-31-18N/A
12/31/2019231-35-28-16N/A
9/30/2019222-23-20-11N/A
6/30/2019216-20-11-3N/A
3/31/2019209-17-14-8N/A
12/31/2018202-21-10-4N/A
9/30/2018195-20-10-4N/A
6/30/2018187-20-15-9N/A
3/31/2018180-27N/A-9N/A
12/31/2017175-27N/A-9N/A
9/30/2017170-33N/A-10N/A
6/30/2017166-32N/A-9N/A
3/31/2017160-34N/A-14N/A
12/31/2016155-33N/A-15N/A
9/30/2016150-36N/A-20N/A
6/30/2016143-35N/A-18N/A
3/31/2016135-32N/A-10N/A
12/31/2015129-27N/A-8N/A
9/30/2015123-22N/A-6N/A
6/30/2015118-16N/A-10N/A
3/31/2015112-14N/A-16N/A
12/31/2014107-16N/A-22N/A
9/30/201499-16N/A-23N/A
6/30/201493-18N/A-21N/A
3/31/201487-17N/A-17N/A
12/31/201381-11N/A-5N/A
9/30/201378-9N/A-2N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: ATRC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: ATRC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: ATRC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: ATRCDie Einnahmen des Unternehmens (12.8% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.4% pro Jahr).

Hohe Wachstumseinnahmen: ATRCDie Einnahmen des Unternehmens (12.8% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: ATRC wird voraussichtlich in 3 Jahren unrentabel sein.

Wachstumsunternehmen entdecken

7D

1Y

7D

1Y

7D

1Y